$-0.01
(Market cap
$27 Mln
Recently Viewed
Clear AllMarket cap
$27 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.5
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-1.2 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-1.9
Debt to Equity
0.3
Book Value
$0.6
EPS
$-0.4
Face value
--
Shares outstanding
25,637,225
CFO
$-35.06 Mln
EBITDA
$-54.51 Mln
Net Profit
$-72.22 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ABVC Biopharma Inc (ABVC)
| -49.8 | 7.0 | -48.1 | 9.6 | -46.5 | -52.8 | -44.1 |
|
BSE Sensex*
| -8.5 | 5.3 | -5.9 | -3.4 | 8.2 | 9.3 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
ABVC Biopharma Inc (ABVC)
| 261.0 | -48.9 | -81.4 | -81.6 | -33.5 | 16.7 | -99.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
ABVC Biopharma Inc (ABVC)
|
1.1 | 27.4 | 0.8 | -7.9 | -324,868.9 | -128.2 | -- | 2.5 |
| 70.1 | 10,349.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 46.2 | 18.2 | |
| 222.1 | 14,164.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 78.1 | |
| 60.7 | 8,115.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.9 | 11,415.1 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.2 | 5.3 | |
| 83.1 | 11,662.4 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 516.7 | 11,754.2 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.5 | |
| 409.7 | 11,724.9 | 2,678.3 | 460.4 | 21.1 | 103.2 | 25.9 | 19.6 | |
| 101.9 | 8,215.5 | 0.0 | -425.4 | -- | -36.7 | -- | 6.6 | |
| 321.9 | 9,603.5 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination... therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. Read more
Chairman & Chief Business Officer
Mr. Eugene Jiang
Chairman & Chief Business Officer
Mr. Eugene Jiang
Headquarters
Fremont, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of ABVC Biopharma Inc (ABVC) is $1.07 (NASDAQ) as of 28-Apr-2026 16:00 EDT. ABVC Biopharma Inc (ABVC) has given a return of -46.53% in the last 3 years.
Since, TTM earnings of ABVC Biopharma Inc (ABVC) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-5.39
|
3.83
|
|
2024
|
-1.44
|
5.77
|
|
2023
|
-0.60
|
2.99
|
|
2022
|
-0.11
|
0.42
|
|
2021
|
-0.79
|
1.15
|
The 52-week high and low of ABVC Biopharma Inc (ABVC) are Rs 5.48 and Rs 0.90 as of 29-Apr-2026.
ABVC Biopharma Inc (ABVC) has a market capitalisation of $ 27 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in ABVC Biopharma Inc (ABVC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.